Retinal Research Institute – Phoenix
Retinal Consultants of Arizona has a strong commitment to medical research and the advancement of treatments for retinal diseases. Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies.
We have been participating in clinical trials since 1998 and are proud that the Retinal Research Institute has become one of the nation’s largest retina & vitreous-specific research organizations. In many instances, RCA is the only retina group in Arizona to offer patient participation in multiple studies addressing multiple eye conditions
Mission / Purpose
Retinal Consultants of Arizona’s mission is to provide the most up to date and effective treatments for patients with retinal diseases.
News
Keep up with new research and findings from recent studies and trials.
Current Studies & Trials
Find out what current studies and trials we are enrolling for.
Interested in a Clinical Trial?
If you or someone you know is interested in more information about our clinical research trials, please contact us.
(602) 222-2221
Follow Us On Social
Pravin U. Dugel MD: As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For
/ Uncategorized /by retinalconsultantsSeptember 4, 2019|Steve Lenier CHICAGO – As innovation in the retina space has grown over the past quarter-century, so has the need for capital to finance those activities. One way innovators are meeting that need is by entering into partnerships with ex-US entities, one of many issues explored by a panel session on financing retina […]
Pravin U. Dugel, MD: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
/ Uncategorized /by retinalconsultantsOPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to […]